MedPath

Shanghai Jiaotong Medical University Attached Ruijin Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

506

Active:29
Completed:61

Trial Phases

6 Phases

Early Phase 1:12
Phase 1:41
Phase 2:102
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (353 trials with phase data)• Click on a phase to view related trials

Not Applicable
144 (40.8%)
Phase 2
102 (28.9%)
Phase 1
41 (11.6%)
Phase 4
34 (9.6%)
Phase 3
20 (5.7%)
Early Phase 1
12 (3.4%)

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Not Applicable
Recruiting
Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
First Posted Date
2025-07-18
Last Posted Date
2025-07-18
Lead Sponsor
Ruijin Hospital
Target Recruit Count
56
Registration Number
NCT07072169
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

Not Applicable
Recruiting
Conditions
Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy
Gastrointestinal Tumors
Interventions
Biological: Neoantigen Personalized Cancer Vaccine
First Posted Date
2025-07-16
Last Posted Date
2025-07-16
Lead Sponsor
Ruijin Hospital
Target Recruit Count
40
Registration Number
NCT07067385
Locations
🇨🇳

Ruijin Hospital, Shanghai, Shanghai, China

6 Weeks Right-Amygdala TIS for Depression

Not Applicable
Conditions
Major Depressive Disorder (MDD)
First Posted Date
2025-07-10
Last Posted Date
2025-07-10
Lead Sponsor
Ruijin Hospital
Target Recruit Count
50
Registration Number
NCT07059143
Locations
🇨🇳

The Affiliated Brain Hospital Of Guangzhou Medical University, Guangdong, China

🇨🇳

Ruijin Hospital, Shanghai, China

🇨🇳

Anding Hospital (Mental Health Center of Tianjin Medical University), Tianjin, China

Investigating the Mechanisms of Welwalk Robot in Restoring Motor Function of the Lower Extremities in Stroke Patients

Not Applicable
Not yet recruiting
Conditions
Stroke
Walking Impairment
First Posted Date
2025-07-10
Last Posted Date
2025-07-10
Lead Sponsor
Ruijin Hospital
Target Recruit Count
38
Registration Number
NCT07057700
Locations
🇨🇳

Shanghai Ruijin Hospital, affiliated to Shanghai Jiao Tong University, School of medicine,, Shanghai, Shanghai, China

Individualized rTMS Synchronized Task Training for Closed-loop Neuromodulation of Post-stroke Motor Dysfunction

Not Applicable
Not yet recruiting
Conditions
Upper Extremity Dysfunction After the Stroke
First Posted Date
2025-07-03
Last Posted Date
2025-07-03
Lead Sponsor
Ruijin Hospital
Target Recruit Count
51
Registration Number
NCT07049211
Locations
🇨🇳

Shanghai Ruijin Hospital, affiliated to Shanghai Jiao Tong University, School of medicine, Shanghai, Shanghai, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 101
  • Next

News

Zambon Secures Chinese Approval for Intravenous Fluimucil Following Successful Phase 3 Trial

Zambon has received Chinese regulatory approval and launched the intravenous formulation of Fluimucil (N-acetylcysteine) for treating respiratory diseases with excessive mucus secretion.

CirCode Biomed's HM2002 Becomes World's First Circular RNA Drug to Receive FDA IND Clearance for Ischemic Heart Disease

CirCode Biomed announced FDA clearance for HM2002, marking the first circular RNA drug to receive IND approval for ischemic heart disease treatment.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.